Archer raises funds for Advanced Materials Business

|

Published 29-NOV-2019 12:30 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Archer Materials Limited (ASX:AXE) has informed the market that it will close its Share Purchase Plan (SPP) on Friday, December 6, 2019 at 5 PM eastern daylight saving time.

The SPP aims to raise $3 million and if total demand for the SPP exceeds that amount the Archer board reserves the right to close the SPP early and scale back applications or elect to increase the amount raised under the SPP.

The proceeds raised from the SPP will provide Archer with the funding required to progress the company’s Advanced Materials Business, in particular the development of the room temperature quantum computer chip, as well as exploration of the company’s tenements.

By way of background, Archer provides shareholders exposure to financial returns from innovative technologies and the materials that underpin them.

The company’s strategy is to build an industry-leading materials technology company that delivers maximum value to shareholders through the commercialisation of assets at various stages of the materials lifecycle.

Archer has strong intellectual property, broad-scope mineral tenements, world-class in-house expertise, a diverse advanced materials inventory, and access to over $300 million of research and development infrastructure.

Ready for full patent application

Most recently the company announced that it had progressed its graphene-based biosensor technology development by building a first-phase prototype device to test the printing and performance of graphene inks produced from the inventory of Carbon Allotropes (graphene inks).

As Finfeed noted earlier in the week, this was a key development milestone towards commercially exploiting the intellectual property underpinning the graphene-based biosensor technology.

The company is now positioned to lodge a full patent application that would give Archer’s exclusive rights to commercially benefit from the intellectual property.

Management noted at the time that the materials and processes used to build the prototypes are not prohibitively expensive which is extremely important in the printable biosensor market.

Archer’s progress in 2019 hasn’t gone unnoticed, particularly over the last six months during which time its shares have soared 70%.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X